Genelux (GNLX) Depreciation & Amortization (CF) (2022 - 2026)
Genelux's (GNLX) quarterly Depreciation & Amortization (CF) came in at $9000.0 in Q1 2026, down 84.75% year-on-year from $59000.0 in Q1 2025, and down 85.0% quarter-over-quarter from $60000.0 in Q4 2025.
Genelux (GNLX) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Genelux's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $9000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 84.75% year-over-year to $9000.0 in Q1 2026; TTM through Mar 2026 was $193000.0, a 8.1% decrease from a year earlier, with the FY2025 full-year figure at $244000.0, up 3.83% from the prior year.
- Depreciation & Amortization (CF) fell to $9000.0 in Q1 2026 per GNLX's latest filing, from $60000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $138000.0 in Q1 2022 and bottomed at $9000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $63000.0 (2025), against an average of $84133.3.
- Across the five-year window, Depreciation & Amortization (CF) soared 65.79% in 2025 and tumbled 84.75% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $138000.0 in 2022, then sank by 31.16% to $95000.0 in 2023, then plunged by 40.0% to $57000.0 in 2024, then advanced by 5.26% to $60000.0 in 2025, then tumbled by 85.0% to $9000.0 in 2026.
- Per Business Quant, the three latest GNLX Depreciation & Amortization (CF) figures stand at $9000.0 (Q1 2026), $60000.0 (Q4 2025), and $61000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,000.00 |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | 95,000.00 |
| Dec 31, 2023 | 95,000.00 |